Body mass index influences the response to infliximab in ankylosing spondylitis
Arthritis Research & Therapy, 05/17/2012
Ottaviani S et al. – This study provides the first evidence that a high body mass index (BMI) negatively influences the response to infliximab (IFX) in ankylosing spondylitis (AS). Further prospective studies, including assessment of the fat mass, pharmacokinetics and adipokines dosages are mandatory to elucidate the role of obesity in AS IFX response.
In 155 patients retrospectively included with active AS, the BMI was calculated before initiation of IFX treatment (5 mg/kg intravenously).
After 6 months of treatment, changes from baseline in BASDAI, Visual Analogue Scale (VAS) pain, C–reactive protein (CRP) level and total dose of Nonsteroidal anti–inflammatory drug (NSAID) was dichotomized with a threshold corresponding to a decrease of 50% of initial level of the measure, into binary variables assessing response to IFX (BASDAI50, VAS50, CRP50, NSAID50).
Whether BMI was predictive of response to IFX therapy according to these definitions was assessed with logistic regression.
Multivariate analysis found a higher BMI was associated with a lower response for BASDAI50 (P=0.0003, OR 0.87 95%CI0.81–0.94VAS50 (P<0.0001, OR 0.87 95%CI[0.80–0.93]), CRP50 (P=0.0279, OR 0.93 95%CI0.88–0.99) and NSAID50 (P=0.0077, OR 0.91 95%CI0.85–0.97criteria.
According to the 3 WHO BMI categories, similar results were found for BASDAI50 (77.6%, 48.9% and 26.5%, P<0.0001), VAS50 (72.6%, 40.4% and 16.7%, P<0.0001), CRP50 (87.5%, 65.7% and 38.5%, P=0.0001) and NSAID50 (63.2%, 51.5% and 34.6%, P=0.06).
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.